Arca
Skip to content
Tools
Tools

UGCG: Ceramide glucosyltransferase

Participates in the initial step of the glucosylceramide- based glycosphingolipid/GSL synthetic pathway at the cytosolic surface of the Golgi.

  • Drugs that act on it: 4
  • Approved: 2
  • In phases 1 to 3: 2
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on UGCG, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4

Approved2

  • Miglustat
  • Eliglustat

Phase 32

  • Lucerastat
  • Venglustat

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Amicus Therapeutics125%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Ceramide glucosyltransferase inhibitor.
      MiglustatApprovedJohnson & JohnsonSmall moleculeInhibitor5
      EliglustatApprovedSanofiSmall moleculeInhibitor3
      LucerastatPhase 3Amicus TherapeuticsSmall moleculeInhibitor6
      VenglustatPhase 3SanofiSmall moleculeInhibitor5

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 18 in all, from ClinicalTrials.gov.
      The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)VenglustatPhase 3Not yet recruitingSanofiNov 10, 2026
      Study With Batten-1 (Miglustat Liquid Formulation) to Treat Ceroid Lipofuscinosis Neuronal 3 (CLN3) DiseaseMiglustatPhase 3Not yet recruitingBeyond Batten Disease FoundationOct 20, 2026
      A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry DiseaseLucerastatPhase 3RecruitingIdorsia Pharmaceuticals Ltd.Aug 21, 2026
      A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseMiglustatPhase 2Active, not recruitingAzafaros B.V.Feb 10, 2026
      GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ LymphomaEliglustatPhase 1 / Phase 2RecruitingChinese PLA General HospitalAug 24, 2025
      GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.EliglustatEarly phase 1Not yet recruitingChinese PLA General HospitalJul 29, 2025
      A Study of Patients With Fabry Disease (US Specific)Lucerastat—RecruitingAmicus TherapeuticsApr 2, 2025
      A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsLucerastatPhase 3RecruitingAmicus TherapeuticsApr 1, 2025
      GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.EliglustatPhase 2RecruitingChinese PLA General HospitalAug 19, 2024
      A Global Prospective Observational Registry of Patients With Pompe DiseaseMiglustat—RecruitingAmicus TherapeuticsNov 7, 2023
      A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseaseLucerastat, VenglustatPhase 3Active, not recruitingSanofiMar 15, 2022
      Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3VenglustatPhase 3Active, not recruitingSanofiFeb 3, 2022
      A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry DiseaseVenglustatPhase 3Active, not recruitingSanofiJan 25, 2022
      A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18MiglustatPhase 3RecruitingAmicus TherapeuticsMar 22, 2021
      A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingLucerastat—RecruitingAmicus TherapeuticsFeb 5, 2020
      A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseaseLucerastatPhase 3Active, not recruitingAmicus TherapeuticsJul 15, 2019
      ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDMiglustatPhase 3Active, not recruitingAmicus TherapeuticsApr 11, 2019
      Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionVenglustatPhase 2Active, not recruitingGenzyme, a Sanofi CompanyJul 25, 2016

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Gaucher disease type I
      0.50
      Niemann-Pick disease type C
      0.50
      Glycogen storage disease II
      0.49
      Niemann-Pick disease
      0.38
      Neurodegenerative disease
      0.37
      Metabolic disease
      0.37
      Bone disorder
      0.37
      Anemia
      0.37
      Hepatosplenomegaly
      0.37

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2063, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q16739, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.